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Abstract
Background: Despite improvements in access to antiretroviral therapy (ART), mortality in people living with human
immunodeficiency virus (PLHIV) is still high and primarily attributed to tuberculosis (TB) infection. In Sub-Saharan
Africa, approximately 80% of HIV-related mortality cases are associated with TB. Relatively little is known about the
incidence of TB among PLHIV in Tanzania and the determinant factors. We report the prevalence and incidence
rate of confirmed TB and determine association with selected demographic and program-related factors based on
data in the national HIV care and treatment program from 2011 to 2014.
Methods: We used the Tanzania National AIDS Control Programme database to obtain information on all HIV
clients enrolled in the HIV care and treatment program between January 2011 and December 2014. We analyzed
retrospective cohort data to assess the prevalence and TB incidence rate per 1000 person-years. A multivariable Cox
proportional hazards regression model was used to estimate hazard ratios and 95% confidence intervals for
putatively associated factors.
Results: Over 4 years, there were 22,071 confirmed cases of pulmonary TB in 1,323,600 person-years. The overall TB
incidence was around 16.7 (95% CI 16.4–16.9) cases per 1000 person-years. The annual incidence rate decreased by
12.4 % from 17.0 (95% CI 16.5–17.4) in 2011 to 14.9 (95% CI 14.5–15.4) in 2014. The TB incidence rate was higher in
persons not using ART and in males than in females. The incidence of TB was higher in patients with advanced HIV
disease and decreased with increasing age. The overall prevalence of TB was 2.2%, with a peak prevalence of 2.5%
in 2013 and was higher among children < 15 years (3.2%) in the same year.
Conclusion: The study found an overall decrease in the incidence of TB in PLHIV. Our results emphasize the need
for early initiation of ART and the provision of TB preventive therapy for those PLHIV without active TB after
intensified TB case-finding.
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Introduction
Tuberculosis (TB) and human immunodeficiency virus
(HIV) co-infection is a significant public health problem
worldwide [1–3]. The lifetime risk of developing active
TB among people living with HIV (PLHIV) maybe 20
times higher than in people without HIV [4]. Tanzania
is among the 30 countries with high TB burden and TB
and HIV co-infection in the world [5]. The National Tu-
berculosis and Leprosy Programme annual report of
2017 indicates that about 31% of all TB-notified cases
had co-infection with HIV [6]. Despite the increased ac-
cess to antiretroviral therapy (ART), mortality in PLHIV
is still high, and TB is the leading cause of mortality [7–
9]. Some studies found that TB preventive therapy by
isoniazid reduces the incidence of TB in HIV-infected
patients [10, 11]. Conversely, some studies have reported
an unacceptably high incidence of TB after ART initi-
ation as a result of immune reconstitution [12, 13].
In 2004, the World Health Organization (WHO) for-
mulated an interim policy to guide member states in
implementing collaborative TB/HIV activities [14] and
further addressed the requirement for collaborative ef-
fort to address the burden of TB and HIV [15]. Subse-
quently, the Ministry of Health in Tanzania formed a
national TB/HIV coordinating body in 2005 for deliver-
ing integrated TB and HIV services to reduce the burden
of TB in PLHIV [14]. In these collaborative activities,
screening for HIV among TB patients occurs in the TB
clinics, likewise, the screening for TB at HIV care and
treatment clinics. The country recommends TB prevent-
ive therapy to be part of the package of care for PLHIV.
All HIV-positive individuals who screen negative for ac-
tive TB are eligible for isoniazid preventive therapy for 6
months [16]
Previous reports from analysis of data collected be-
tween 2004 and 2012 in Dar es Salaam, the largest city
in Tanzania, reported the TB incidence rate of 7.9/100
person-years before ART initiation and 4.4/100 person-
years for patients receiving ART [17]. However, the re-
ported TB incidence rates among HIV-infected patients
before and after ART initiation were from HIV-infected
cohort in the largest city in the country, which might
not reflect the country-wide incidence rates. Also, the
incidence rate might change with time, taking into con-
sideration the implementation of collaborative TB and
HIV activities. We, therefore, analyzed data in the na-
tional HIV care and treatment program collected from
2011 to 2014 to determine the country-wide incidence
of TB and among PLHIV related factors.
Material and methods
Design, setting, and population
The descriptive-analytical study of retrospective cohort
data is routinely collected between 2011 and 2014 at
HIV service delivery clinics and archived in the National
AIDS Control Programme database. The data included
information from all clients attending HIV care and
treatment services, as stipulated in the national program
for HIV management [16]. All HIV patients in Tanzania
receive the same quality of care and treatment services
at care and treatment clinics (CTC). The clinics have
been set up, in both public and private hospitals, health
centers and dispensaries, throughout Tanzania. An inte-
gral part of the delivery of care and treatment is to en-
sure that effective monitoring and evaluation of the HIV
program takes place.
Care and treatment service
Provision of quality HIV care and treatment service was
guided by the national HIV/AIDS care and treatment
guideline [16]. Patients eligible for ART had baseline
CD4 counts below 200 cells/mm3 regardless of WHO
stage or baseline CD4 counts between 200 and 350 cells/
mm3 and be in baseline WHO stage 3 or 4 or baseline
WHO stage 4 regardless CD4 counts. Also, all adult pa-
tients with confirmed TB status during clinic enrolment
were eligible for ART. Before the initiation of ART in
any patient, health care workers conduct a complete as-
sessment of the patient, starting with in-depth medical
history followed by a head-to-toe physical examination,
including WHO clinical staging. TB screening question-
naire was administered at baseline and during scheduled
follow-up visits.
The country introduced a new guideline in 2012 to
combat the poor enrolment of the pediatric population
on ART that directed treatment of all HIV-positive chil-
dren, under the age of 15 years, with suitable ART re-
gimes [16]. Health care workers evaluated HIV-infected
children for TB disease at the time of HIV diagnosis; at
any time when they present with symptoms suggestive
of TB during a scheduled follow-up visit or when they
have a history of a new contact to an adult with TB. A
standardized score chart, which is TB symptom-
screening, was a tool used for screening of tuberculosis
in children.
Data management
Primary data generated in the CTC was captured on
facility-held information collection tools designated as
CTC2 card. Information from CTC2 cards at the health
facility level is aggregated either manually or electronic-
ally at different levels up to the national level. The
manually aggregated data is electronically captured at
the national level. Moreover, patient-level data from
health facilities with electronic CTC2 databases is
exported to the national level. In the end, electronically
available aggregated data at the national level and
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patient-level data create a macro database designated as
CTC3.
Definition of variables
Adult patients are referred to as those aged 15 years and
older, as described in the National guideline for the
Management of HIV and AIDS in Tanzania [16]. HIV
clients “non-ART” are all patients who have enrolled in
CTC but have not yet initiated ART. HIV clients “on
ART” are all patients who have initiated ART. The date
of enrolment in CTC was defined as the first date docu-
mented in the database, and enrolment year extracted
from the first visit date. The date first initiated on ART
was taken from the CTC record if it was recorded and
otherwise defined as the first date recorded to receive
ART. Patients were defined as the loss to follow-up
(LTFU) if they had not attended any clinic in the 6
months preceding 31 December 2014 and were not
known to have died. TB incidence was defined as a new
bacteriologically confirmed case of TB by smear, Gen-
Xpert, or culture between1 January 2011 and 31
December 2014.
Data analysis
Abstracted data were analyzed using StataCorp 2015
(Stata Statistical Software: Release 14. College Station,
TX: StataCorp LP). The individual-level data were used
to calculate the prevalence, incidence rate, and risk fac-
tors for the occurrence of tuberculosis. The analysis in-
cluded all individuals who attended CTC from 1 January
2011 to 31 December 2014. The prevalence of tubercu-
losis was calculated for the entire patient population and
separately for each program year. Further analyses strati-
fied the subjects by sex, age group, and ART status
(ART and Non-ART).
Patient characteristics at the time of incidence of TB
were described by the year using frequencies and per-
centages for categorical variables. Patients seen in 2011
were followed until one of the following happened: the
first episode of TB, or censored due to death, lost-to-
follow-up, or on 31 December 2014. We divided the
interval into the years to obtain annual TB incidence.
We calculated the TB incidence rate by dividing the
total number of TB incidence by the 1000 person-year
of observation. A multivariable Cox proportional hazards
regression model was used to estimate hazard ratios ad-
justed for all covariates and 95% confidence intervals
(CI) for factors associated with TB incidence. Kaplan-
Meier estimation methods were used to calculate the
probabilities of cumulative TB incidence after enrolment
into the clinic, stratified by baseline characteristics of
interest.
Results
Data were extracted and analyzed from records of 527,
249 individuals with a total of 11,539,844 clinical en-
counters enrolled in HIV care and treatment services be-
tween 2011 and 2014, with an average of 6 encounters
per year (Table 1).
Prevalence of tuberculosis
The number of cases and prevalence of TB among HIV
clients enrolled in care and treatment clinics in the
period of 2011 to 2014 are summarized in Table 2. The
overall prevalence was 2.2%, with a peak of 2.5% in the
year 2013. Noticeably higher TB prevalence was found
among children < 15 years, which peaked at 3.2% in
2013. Overall, TB was more reported in males than in
females, and the differences were consistent over the 4
years. The highest prevalence in males was 3.5% ob-
served in 2013. Throughout the 4 years, there was a rela-
tively lower prevalence of TB among PLHIV on ART
than those not on ART.
Incidence of tuberculosis
We analyzed the incidence of TB by following up on pa-
tients who visited the HIV clinics beginning in each of
the years from 2011 to 2014. The outcome of interest
was confirmed TB. Over the 4 years, there were 22,071
confirmed cases of TB among clients attending CTC
(Table 3). The overall incidence of TB was around 16.7
(95% CI 16.4–16.9) cases per 1000 person-years. The an-
nual incidence rate per 1000 person-years was 17.0 (95%
CI 16.5–17.4) in 2011 and 14.9 (95% CI 14.5–15.4) in
2014, indicating a 12.4 % decrease over the 4 years. The
incidence rate was significantly lower among females,
13.9 (95% CI 13.7–14.2) per 1000 person-years than
males 22.8 (95% CI 22.4–23.3) per 1000 person-years.
The incidence rate of TB was fourfold more common in
non-ART patients as compared to ART patients, being
47.2 (46.1–48.3) per 1000 person-years versus 12.8
(12.6–13.0) per 1000 person-years. The risk of develop-
ing TB was significantly lower in adults (hazard ration
less 1) compared to children below 15 years and in-
creased with stage of clinical HIV disease (hazard ration
from 2 in stage 2 to 12 in stage 4) (Table 3).
Table 1 Number of individuals and clinic encounters in HIV
care, treatment, and support program in Tanzania from 2011 to
2014
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Cumulative probability of TB incidence
Kaplan-Meier curves were used to assess the cumulative
probability of TB incidence over time and stratified by
baseline variables of age and sex. The overall probability
of TB incidence was 50% by 2 years since enrollment
and reached around 65% in 4 years. The hazard of TB in-
cidence was highest in the first year of enrolment (Fig. 1).
The cumulative probability of TB incidences was similar
between adults and children in the first 6 months, progres-
sively increasing more in adults than children after 6
months. Two years after, the cumulative enrollment prob-
ability for TB incidence was 50% in children while it
reached around 60% among adults (Fig. 2). There was a
clear difference in the cumulative probability of TB
Table 2 Prevalence of TB among individuals enrolled in HIV care, treatment, and support program in Tanzania from 2011 to 2014
Characteristics 2011 2012 2013 2014 Total
N (%) N (%) N (%) N (%) N (%)
Overall 8765 (2.1) 9798 (2.3) 11,212 (2.5) 9857 (1.9) 39,632 (2.2)
Age group
< 15 years 687 (2.1) 784 (2.3) 1066 (3.2) 854 (2.4) 3391 (2.5)
≥ 15 years 8078 (2.1) 9014 (2.3) 10,146 (2.4) 9003 (1.9) 36,241 (2.2)
Sex
Male 3858 (2.9) 4474 (3.2) 5066 (3.5) 4681 (2.8) 18,079 (3.1)
Female 4907 (1.8) 5324 (1.8) 6146 (2.0) 5176 (1.5) 21,553 (1.7)
ART status
ART 1145 (1.5) 883 (1.4) 630 (1.2) 699 (1.2) 3357 (1.3)
Non-ART 7620 (2.3) 8915 (2.4) 10,582 (2.6) 9158 (2.0) 36,275 (2.3)
Table 3 Incidence of tuberculosis among individuals enrolled in HIV care, treatment, and support program in Tanzania in 2011 to 2014
Variable TB cases 1000 person-years TB incident rate/1000 person-years (95%CI) Hazard ratio (95% CI)
Overall 22,071 1323.6 16.7 (16.4–16.9) -
Year of diagnosis
2011 5366 316.2 17.0 (16.5–17.4) 1
2012 5254 317.9 16.5 (16.1–17.0) 1.07 (1.02–1.14)
2013 6356 348.5 18.2 (17.8–18.7) 1.15 (1.09–1.21)
2014 5095 342.3 14.9 (14.5–15.4) 0.84 (0.80–0.89)
Sex
Male 9306 407.7 22.8 (22.4–23.3) 1
Female 12,764 916.9 13.9 (13.7–14.2) 0.65 (0.64–0.67)
ART status
Non-ART 7026 148.9 47.2 (46.1–48.3) 1
ART 15,045 1152.7 12.8 (12.6–13.0) 0.47 (0.46–0.49)
HIV clinical stage
1 844 180.0 4.7 (4.3–5.0) 1
2 2306 300.1 7.7 (7.4–8.0) 2.31 (2.09–2.55)
3 13,233 604.8 21.9 (21.5–22.2) 10.2 (9.31–11.09)
4 5214 216.7 24.1 (23.4–24.7) 12.3 (11.2–12.45)
Age group (years)
< 15 2034 97.5 20.8 (20.0–21.8) 1
15–24 1210 70.4 17.2 (16.3–18.2) 0.66 (0.63–0.78)
25–34 5514 323.1 16.9 (16.4–17.3) 0.78 (0.75–0.81)
35–44 7554 458.9 16.5 (16.1–16.8) 0.93 (0.90–0.97)
45–54 3990 253.9 15.7 (15.3–16.2) 0.94 (0.90–0.98)
55+ 1754 116.9 15.0 (14.3–15.7) 0.87 (0.83–0.92)
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incidence between males and females. By 6months, the
cumulative probability of TB incidence among males
reached 50% compared to 25% among females, who
reached 50% after 3 years (Fig. 3).
Discussion
We conducted an assessment of the occurrence of a first
episode of pulmonary tuberculosis (PTB), involving indi-
viduals whose first visits at HIV care and treatment ser-
vices occurred between January 2011 and December
2014. As a result, the study included a total of 527,249
individuals with a total of 11,539,844 clinical encounters
at health facilities implementing TB and HIV collabora-
tive activities. The overall TB incidence rate was around
16.7 (95% CI 16.4–16.9) cases per 1000 person-years
with annual incidence rate decreasing from 17.0 to 14.9
per 1000 person-years, representing around 12% de-
crease over the 4 years.
The observed incidence of TB in PLHIV on ART re-
ported in this study (12.8 per 1000 person-years) is on
Fig. 1 Cumulative probability of TB incident after enrollment to HIV care and treatment
Fig. 2 Cumulative probability of TB incident after enrollment to HIV care and treatment by age
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the lower side compared to observed incidences in prior
studies conducted among adults in Tanzania [17]. The
finding may be a reflection of continuous improvement
in HIV and TB collaborative activities and the reduction
of TB incidence in HIV programs. In support, we ob-
served in this analysis that in patients receiving ART, the
decrease in TB incidence went from 13.5 (95% CI 13.1–
14.0) per 1000 person-years in 2011 to 11.0 (95% CI
10.6–11.3) in 2014 a decrease of 19% over the 4 years. In
contrast, those not on ART, the TB incidence went from
33.3 (95% CI 31.8–34.8) per 1000 person-years in 2011
to 104.9 (95% CI 99.7–110.3) per 1000 person-years in
2014, a three-fold increase in the incidence of TB. The
reported incidences in other parts of African countries
range from 0.9 to 7.9 cases per 100 PY [18–21].
As observed in this analysis and reported in other
studies, the use of ART has a significant advantage on
the reduction of incidence of TB, evidenced by a marked
low incidence of TB among persons on ART compared
to those not on ART [17, 22, 23]. The findings are con-
ceivable because the TB infection and reactivation have
been associated with the degree of immune suppres-
sion, which improves after the start of ART [24]. In
individuals not on ART, HIV infection increases sus-
ceptibility to TB and is the most potent factor in
transferring latent or recently acquired TB infection
to active clinical diseases [25, 26]. Our findings
emphasize the need for TB preventive therapy, which
has been found to reduce the risk of developing tu-
berculosis and prolongs survival [27].
The TB incidence in the current study was signifi-
cantly associated with advanced HIV disease defined by
WHO clinical stages. Our findings are consistent with
previous findings and support the known benefit of early
HIV diagnosis and treatment [28]. There is a much
higher risk of HIV and TB co-infected patients to de-
velop active TB either from the latent infection or rapid
progression of a new infection, especially in advanced
HIV disease [29]. TB incidence as a result of immune re-
constitution after initiation of ART is likely to occur in
advanced HIV disease [12, 13]. Although this study did
not record immune reconstitution inflammatory syn-
drome, the majority of TB incidence among patients
with advanced HIV disease occurred within 2months
after ART initiation, as previously observed [12, 13]
The study found a higher risk of TB among males
compared to females, which is comparable to other stud-
ies [2, 30, 31]. The most probable reason to explain this
difference could be the biological differences in disease
and disease presentation, which favors women [32, 33].
Furthermore, men are more likely to report predisposing
factors for TB, like smoking than females [34].
PLHIV, aged below 15 years, had a significantly higher
risk of TB incidence than adults. However, encour-
agingly, the observed overall incidence of TB in chil-
dren (20.8 cases per 1000 PY) is less compared to
findings from a previously reported cohort study in
Tanzania (5.2 cases per 100 PY) [35]. This signifies
the effort in increasing access to pediatric HIV and
TB care and treatment in Tanzania [36].
The major strength of this study is that it drew on a
large and nationally representative sample from a coun-
try with a significant burden of TB and HIV. It has pro-
vided some insights into the situation of TB in clinical
Fig. 3 Cumulative probability of TB incident after enrollment to HIV care and treatment by age and sex
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services for HIV care and treatment in Tanzania. Never-
theless, the analysis excluded patients without bacterio-
logical confirmation, which lead to underestimation of
the magnitude of TB. Besides, many of our facilities may
not be able to perform a bacteriological diagnostics test,
which has high sensitivity and specificity, instead of de-
pending on radiological and clinical diagnoses. The
other limitation is that the data come from the elec-
tronic CTC database, which is used in the larger and
better run clinics. The situation reported here might not
be the same in smaller health facilities that have not pro-
vided electronic data.
Conclusion
The study found an overall decrease in the incidence of
TB in PLHIV and demonstrated more among those on
ART, adult, female, and low HIV clinical stage. Our re-
sults reinforce the recommendation of HIV test and
treat, intensified TB case findings, and TB preventive
therapy for those PLHIV without active TB.
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